1. Scrip

How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value

 
• By Emily Hayes

With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.

Cost and Value Concept, abstract coins piles. Conceptual image for marketing analysis.

Once a poster child for high-cost cancer drugs, Roche's VEGF inhibitor Avastin is now being heralded as more cost effective as an add-on maintenance treatment in advanced ovarian cancer than PARP inhibitors, and has potential for continuous use, according to new studies presented at the American Society of Clinical Oncology (ASCO) meeting in June.

Platinum-based chemotherapy is standard treatment for ovarian cancer. Patients who relapse six months after treatment are considered "platinum-sensitive" and eligible...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.